NewLink nets $20M Ebola milestone from Merck

February 26, 2015 | By
Tools

NewLink's ($NLNK) Ebola vaccine tie-up with Merck ($MRK) continues to pay off. The Iowa-based company has triggered a milestone payment from the pharma giant worth $20 million, it said last week, and it'll put the money back into its vaccine work for infectious diseases. Release

Filed Under
, ,

Comments

Press Releases
  • Opening Arguments Today in Largest US Pharma Theft Civil Suit
  • Award of Funding for Next Stage of US Department of Defense Programme to Develop Genedrive® Biohazard Identification Tests
  • Men in England to finally have routine access to UK-discovered prostate cancer medicine Zytiga (abiraterone acetate) before chemotherapy
  • Switching to Remsima®▼ (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies
  • The Myriad myRisk Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer
  • More Press Releases
Featured Jobs
> Need a job? Need to hire? Visit our jobs site.